Alginate@polydopamine@SiO2 Microcapsules with Controlled Porosity for Whole-Cell Based Enantioselective Biosynthesis of (S)-1-phenylethanol
Li Wang,Bo-Bo Zhang,Xiao-Yu Yang,Bao-Lian Su
DOI: https://doi.org/10.1016/j.colsurfb.2022.112454
IF: 5.999
2022-01-01
Colloids and Surfaces B Biointerfaces
Abstract:Whole-cell biocatalysis, owing to its high enantioselectivity, environment friendly and mild reaction condition, show a great prospect in chemical, pharmaceutical and fuel industry. However, several problems still limit its wide applications, mainly concerning the low productivity and poor stability. Although the biocatalyst encap-sulated in the most-commonly-used alginate hydrogels demonstrate enhanced stability, it still suffers from low biocatalytic productivity, long-term reusability and poor mass diffusion control. In this work, hybrid algina-te@polydopamine@SiO2 microcapsules with controlled porosity are designed to encapsulate yeast cells for the asymmetric biosynthesis of (S)-1-phenylethonal from acetophenone. The hybrid microcapsules are formed by the ionic cross-linking of alginate, the polymerization of dopamine monomers and the protamine-assisted colloidal packing of uniform-sized silica nanoparticles. Alginate provides the encapsulated cells with highly biocompatible environment. Polydopamine enables to stimulate the biocatalytic productivity of the encapsulated yeast cells. Silica shells can not only regulate the mass diffusion in biocatalysis but also enhance the long-term mechanical and chemical stability of the microcapsules. The morphology, structure, chemical composition, stability and molecular accessibility of the hybrid microcapsules are investigated in detail. The viability and asymmetric bioreduction performance of the cells encapsulated in microcapsules are evaluated. The 24 h product yield of the cells encapsulated in the hybrid microcapsules shows 1.75 times higher than that of the cells encapsulated in pure alginate microcapsules. After 6 batches, the 24 h product yield of the cells encapsulated in the hybrid microcapsules is well maintained and 2 times higher than that of the cells encapsulated in pure alginate microcapsules. Therefore, the hybrid microcapsules designed in this study enable to enhance the asymmetric biocatalytic activity, stability and reusability of the encapsulated cells, thus contributing to a sig-nificant progress in cell-encapsulating materials to be applied in biocatalytic asymmetric synthesis industry.